




已閱讀5頁(yè),還剩20頁(yè)未讀, 繼續(xù)免費(fèi)閱讀
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Liverfailure Sub acuteliverfailureLowestriskofcerebraloedema encephalopathyEasilyconfusedwithCLDAscitesLowestchanceofspontaneoussurvival Hyper acuteliverfailureAcuteliverfailureGreatestriskofcerebraloedema CVSfailureGreatestchanceofspontaneoussurvival CauseAgentresponsibleViralHepatitisA B DE othersDrugrelatedIdiosyncraticanddoserelatedToxinsCarbontetrachloride PhosphorousAmanitaphalloidesVasculareventsIschemichepatitis Budd Chiari VOD heatshockliverOtherPregnancyrelated Wilsondisease lymphoma PrincipleCausesofAcuteLiverFailure NopreviousliverdiseaseVariousdefinitionsJaundiceorsymptomstoencephalopthy DecompensatedchronicliverdiseaseDecompensationwithsepsisBacterialperitonitis Rxas peritonitis Bacteraemia chest urineVaricealbleed frequentlyseptic endoscopicskills TIPSEncephalopathyHepatorenalfailureAlcoholichepatitis steroids pentoxifylline feed deltabilirubinDifferentialwithALF HistoryPatternofLFT sImaging ultrasound CTscanBiopsy varyrarelyindicatedLivertrauma Multisystemdisease CoagulopathyINRimportantprognosticindicatorinestablishedALFPlateletdysfunctionDIC rareMetabolicInsulinresistance ClarkeetalHepatologyHyperlactataemia BernaletalLancet2002 usefultotrackLivernetproduceroflactateMurphyetalCritCareMed2001P04 Mg Na glucose K pHHighincidenceofpancreatitisNutritionFrequentpoorrecentoralintake vomitingNoevidenceforproteinrestrictionineitheracuteorCLDGastricprophylaxisIncreasedmetabolicrequirementsWalshetalCCM2000 28 3 649 54 Renalfailure Common45 ofallcasesMultifactorial frequentlyprerenal ATNratherthanHRSRoleofintra abdominalpressureSpecificassociationswithviraldisease alcohol auto immuneCRRTorslowhaemodialysisisidealAnticoagulationepoprostenol heparin regionalanticoagulation citrate Infection ALF ImpairedinnateandcellularimmunityBacterialinfection335of887patients 550episodes Severesepsis58 mortalitySepticshock98 mortalityFungalinfection99of887 11 64 mortalityRolandoetalHepatology200032 734 31 4 872ComponentsofSIRSassociatedwithencephalopathyRolandoetalHepatology2000 32 734 9 VaqueroetalGastroenterology2003 125 755 64 ShawcrossDetalJHepatolinpressCultures Antibiotics broadinitially 5 7courseAntifungalsNobenefittoroutineprophylaxisorSelectivegutdecontaminationRolandoetalSeminLiverDis1996 16 389 402 RolandoetalLiverTransSurg1996 2 8 13 VasopressorsinALF Whatmeanarterialpressure Clinicalexamination invasiveDeterminedbyJVsaturationandICP autoregulatingornot Whichdrug DeterminefluidresponsivenessinitiallyWhateveryoucangetyourhandsonInsepsisandMOFepinephrinemaybedetrimentalincreasessplannchnicV02 glucoseturnoverMeierHellmanetal1997CritcareMedPhenylephrine decreasedflowwithdecreaseinsplV02ReineltCritCareMed1999 27 325NorepinephrineasfirstchoiceVasopressinmaybepotentiallydetrimental cerebralcomplicationsandpotentialsplanchnicischaemia ResultsstratifiedaccordingtobloodpressureondayofSST 0 500 1000 1500 NSP 0 01P 0 05 Baseline Increment Peak P 0 001 HarryetalHepatology2002 mortalityassociatedwithlowerbaselineandincrement p 0 05 correlateswithAPACHEIIIandSAPSNocorrelatewithotherparametersotherthancholesterol 57 ofpatientshaveabnormalsynacthenresponsehypotensionassociatedwithlowerbaselineandincrement p 0 05 Marik2005CCM53 1254LDLcholesteroldidseparategroups8 2 7 6vs28 4 14Mortality39 vs56 75 ofthoseonpressorshadabnormalresponse Encephalopathy HEofAcuteLiverFailureHepatocellularfailureRapidonsetCerebraloedemaMyoinositollevelsnotreducedCytotoxicandvasogenic PortalSystemicEncephalopathyPortalsystemicshuntspontaneouscollateralSurgicalTIPPSNotatriskofcerebraloedemaPrecipitatingfactorsSepsisSBPRxfluids AlbuminAvoidrenalfailureCNSactivedrugsElectrolyteabnormalitiesDiuretics overuseGastrointestinalbleeding HepaticencephalopathyinCLD Notacauseofdeath ProvidingtheairwayismanagedTreatprecipitatingcause sepsisscreen fluids AssociationofSIRSwithencephalopathyFeed stdprotein highcalorie fibrecontentideallyvegetablebasedLactuloseandenemas cleaningoracidificationAls NielsonBMJ2004 328 1064Non absorbableantibioticsDecreasingammoniatherapies i ornithineand ii benzoateBenzodiazepineantagonists noefficacyPomiers LayrarguesHepatology198910 969Sedation realriskinwardenvironmentYes theyareamenace upallnight climbingintothewrongbed shouting Progressiveneuropsychiatricsyndrome progressiveneuralinhibitionOccursinbothacuteandchronicliverdiseaseClinicalstatemaychangeveryrapidly IncidenceofcerebraloedemaReviewed229patientsGradeIII IVcoma1999 2002IncidenceHyperacute 24 Acute 23 Subacute 9 NH4NeurosteroidsInflammatoryresponse LarsenNeurochemInternational2004 44 ShawcrossLancet3652005 Increasedammoniaincerebraldeaths splanchnicammoniaproductionLarsenetalHepatology1998NH4cutoff124 pH cerebraloedema NH4predictoutcomeBhatiaVGut2005PartialpressureNH4correlateswithlevelofencephalopathyKramerHepatology2000 21CBFvariable lossofautoregulationtopressureTerlipressininALFShawcrossetal Hepatology2004 39 2 464 70 JalanetalGastroenterology2004 27 1338Cooledto32 33oC PREPOSTn 7ICP45 25 49 16 13 17 CBF103 25 134 44 24 75 CPP45 37 56 70 60 78 CI9 8 7 13 5 1 4 3 6 1 ArterialNH4343 109 490 to259 100 453 Uptake2 6 0 6 6 3 to 0 3 3 1 1 4 JalanetalLancet354 9185 11641999 N 14 ReductioninICPintreatmentgroup p 0 005 MurphyetalHepatology2004 39 2 464 70 Reducedriskofintracranialhypertension p 0 05 AgitationandairwaymanagementGradeIII IntubateventilateandsedatewithopiateandpropofolControlventilation avoidalkalosisPosition 10to20degreesheadupInsertreversejugularline JVsat55to80 Tightcontrolofglucose K pH Na 145 150mmol L MurphyetalHepatology2004 39 2 464 70Ammonia earlyCRRTMAP 65 frequentlynotautoregulating needtomeasureICPTreat ICP pupillaryabnormalitiesMannitol150ml20 osmolarity150 pressors fever hyperacuteandacute pupilllaryabnormalitiesTemperature avoidfever hypothermiashouldnotbeundertakenroutinely Currentlyavailable PhaseIIIstudywithBALDemetriouetalAnnSurg2004 239660 670 MARSTherapyMitzneretalLiverTranspl2000 6 277 286 HeemannetalHepatology2002 36 949 58 24patientswithCLDand acuteliverinjury MARSgroup reducedbileacids bilirubin encephalopathyControls biochemistrystatic worseningencephalopathyMARS11 12 SMT6 12 P 0 05 6mnthsurvival6 12MARSvs4 11 CoagulopathyandMARStreatmentinCLDDoriaetalClinicaltransplantation2004 18 365SinglePassAlbuminDialysis SPAD Clearanceofbilirubin bileacids NH4 improvedSauerHepatology2004 39 1048 MARSNathanetalLiverTransplant2004 10 1109LaiWetalIntCareMed2005 18patientswithalcoholrelatedAoCLDrandomizedtoMARSorSMTover7daysSignificantimprovementinencephalopathyNochangeinrenalfunctionorcreatinineNochangeinammoniaorcytokinelevels TNF IL 6 IL 10 IL 8 MDA MELDfellinbothgroups10patientswithALFgradeIII IVcomaTreated8hourson2consecutivedaysIncreaseSVRIonfirstRx1114 196to1432 245 changesnotsignificantbyendofsecondRxNochangeinICP14 5 7 25 to14 3 25 MARS SMTvs SMTAcuteonChronicLiverDiseasen 70SignificantimprovementsinencephalopathygradeNodifferencesinsurvivalHassaneinetalAASLD2004 OutcomeofCLDinITUWehleretalHepatology2001 34 255 261 143patients observationalstudy ApacheIII 90 pressors Clinicaljaundice 92 1monthMortalityvs11 inthosewith 3criteria420patientsGildeaChest2004 126 1598 30patientswithHRF8 3030daysurvival median21 Ventilatedsurvival0 15Non ventilatedsurvival8 15NodifferenceINR alb pressorsJGastroenterologyandHepatologyWitzkeetal200419 1369 AccuracyofICUscoringsystems ChildPugh0 72MELD0 72APACHEII0 78SOFA0 80 363patientswithCLDadmittedtoLITU PSE CVS RENALfailure 98 MortalitySOFAscorecutoff 13 Guidelinesforreferral ArterialpH3 0day2or 4 0thereafterINR 1 8oliguriaand
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 線(xiàn)下演出市場(chǎng)復(fù)蘇中的藝人個(gè)人品牌塑造與傳播報(bào)告001
- 探索2025年開(kāi)放銀行生態(tài)構(gòu)建中的金融科技與金融科技企業(yè)可持續(xù)發(fā)展研究報(bào)告
- 新藥研發(fā)新方向2025:靶點(diǎn)發(fā)現(xiàn)與驗(yàn)證技術(shù)實(shí)戰(zhàn)解析
- 2025年天然植物精油護(hù)膚品牌市場(chǎng)拓展與品牌合作案例報(bào)告001
- 汽車(chē)行業(yè)供應(yīng)鏈金融風(fēng)險(xiǎn)防范與優(yōu)化:2025年風(fēng)險(xiǎn)防范策略案例報(bào)告001
- 2025年醫(yī)藥行業(yè)研發(fā)外包(CRO)模式下的質(zhì)量控制與持續(xù)改進(jìn)報(bào)告
- 2025年醫(yī)藥行業(yè)CRO模式下的臨床試驗(yàn)數(shù)據(jù)管理與分析報(bào)告
- 城市商業(yè)綜合體智能化系統(tǒng)設(shè)計(jì)與智慧家居評(píng)估報(bào)告
- 2025年醫(yī)藥企業(yè)研發(fā)外包(CRO)模式藥物研發(fā)醫(yī)療器械研發(fā)與注冊(cè)報(bào)告
- 2025年體檢行業(yè)市場(chǎng)前景展望與服務(wù)質(zhì)量提升策略報(bào)告001
- 學(xué)校預(yù)防性侵教育活動(dòng)開(kāi)展情況總結(jié)
- 廣州版四年級(jí)英語(yǔ)下冊(cè)各單元知識(shí)點(diǎn)歸納及同步練習(xí)
- 廣東省廉江市實(shí)驗(yàn)學(xué)校2022-2023學(xué)年數(shù)學(xué)五年級(jí)第二學(xué)期期末聯(lián)考試題含答案
- 湖南三支一扶考試歷年真題
- 心肺運(yùn)動(dòng)試驗(yàn)-PPT-醫(yī)學(xué)課件
- 2023年小學(xué)數(shù)學(xué)壓軸幾何圖形經(jīng)典30題匯編
- 農(nóng)業(yè)推廣經(jīng)營(yíng)服務(wù)相關(guān)知識(shí)
- 鐵路工程預(yù)算定額標(biāo)準(zhǔn)說(shuō)明
- 滅火和疏散應(yīng)急預(yù)案流程圖
- 2023-2024學(xué)年云南省景洪市小學(xué)語(yǔ)文四年級(jí)期末評(píng)估試題
- 強(qiáng)夯施工工藝流程圖
評(píng)論
0/150
提交評(píng)論